Johnson & Johnson (NYSE:JNJ) Shares Purchased Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Johnson & Johnson stock on March 5th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE:JNJ traded up $0.26 during midday trading on Wednesday, reaching $153.88. 3,885,092 shares of the company were exchanged, compared to its average volume of 7,957,985. The stock has a fifty day simple moving average of $159.39 and a two-hundred day simple moving average of $155.10. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market cap of $370.83 billion, a PE ratio of 23.14, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Verity & Verity LLC grew its holdings in Johnson & Johnson by 7.0% during the first quarter. Verity & Verity LLC now owns 113,496 shares of the company’s stock valued at $18,822,000 after purchasing an additional 7,411 shares during the period. NorthCrest Asset Manangement LLC boosted its position in shares of Johnson & Johnson by 6.6% in the first quarter. NorthCrest Asset Manangement LLC now owns 251,286 shares of the company’s stock valued at $41,673,000 after acquiring an additional 15,591 shares during the period. Liberty Capital Management Inc. increased its holdings in Johnson & Johnson by 3.8% during the 1st quarter. Liberty Capital Management Inc. now owns 6,205 shares of the company’s stock worth $1,029,000 after acquiring an additional 227 shares during the period. Legacy Trust boosted its holdings in Johnson & Johnson by 2.9% in the 1st quarter. Legacy Trust now owns 42,095 shares of the company’s stock valued at $6,981,000 after purchasing an additional 1,173 shares during the period. Finally, Farrell Financial LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth $211,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday. Raymond James cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.78.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.